← Back to Clinical Trials
Recruiting NCT07385092

NCT07385092 Continuous Vital Sign Monitoring Versus Routine Spot-checks in Patients After Non-cardiac Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07385092
Status Recruiting
Phase
Sponsor Universitätsklinikum Hamburg-Eppendorf
Condition Vital Sign Monitoring
Study Type INTERVENTIONAL
Enrollment 264 participants
Start Date 2026-02-24
Primary Completion 2026-11-01

Eligibility & Interventions

Sex All sexes
Min Age 45 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Unblinded continuous vital sign monitoringBlinded continuous vital sign monitoring

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 264 participants in total. It began in 2026-02-24 with a primary completion date of 2026-11-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The "COME ON, NOW!" trial is a randomized, single-center trial in patients recovering from non-cardiac surgery on normal wards investigating whether continuous vital sign monitoring - compared to routine spot-checks by nurses - reduces the total duration of abnormal vital signs per hour during the first 48 hours after admission to the normal ward.

Eligibility Criteria

Inclusion Criteria: Consenting patients ≥45 years scheduled for elective non-cardiac (abdominal and thoracic) surgery with planned postoperative admission to a normal ward after an overnight stay in an advanced post-anesthesia care unit. Exclusion Criteria: * Emergency surgery * Pregnancy * Impossibility to perform continuous monitoring with the Radius VSM sensor (Masimo, Irvine, CA) * Atrial fibrillation * Patients designated Do Not Resuscitate, or are receiving end-of-life care

Contact & Investigator

Central Contact

Kristen K Thomsen, MD

✉ kr.thomsen@uke.de

📞 +4940741070215

Principal Investigator

Bernd Saugel, MD

PRINCIPAL INVESTIGATOR

Universitätsklinikum Hamburg-Eppendorf

Frequently Asked Questions

Who can join the NCT07385092 clinical trial?

This trial is open to participants of all sexes, aged 45 Years or older, studying Vital Sign Monitoring. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07385092 currently recruiting?

Yes, NCT07385092 is actively recruiting participants. Contact the research team at kr.thomsen@uke.de for enrollment information.

Where is the NCT07385092 trial being conducted?

This trial is being conducted at Hamburg, Germany.

Who is sponsoring the NCT07385092 clinical trial?

NCT07385092 is sponsored by Universitätsklinikum Hamburg-Eppendorf. The principal investigator is Bernd Saugel, MD at Universitätsklinikum Hamburg-Eppendorf. The trial plans to enroll 264 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology